TY - JOUR
T1 - Carfilzomib boosted combination therapy for relapsed multiple myeloma
AU - Steiner, Raphael E.
AU - Manasanch, Elisabet E.
N1 - Publisher Copyright:
© 2017 Steiner and Manasanch.
PY - 2017/2/15
Y1 - 2017/2/15
N2 - Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate approval of this medication by regulatory agencies has been an important step toward improving clinical outcomes in multiple myeloma. Although initially approved as a single agent for the treatment of multiply relapsed and/or refractory myeloma, in the USA, it is now widely used in the early relapse setting in combination with lenalidomide and dexamethasone. Carfilzomib has also been studied in combination with second-generation immunomodulatory drugs, histone deacetylase inhibitors, alkylating agents and other novel medications. In this review article, we will discuss the efficacy, safety, tolerability and quality of life of carfilzomib-based combination therapies, as well as novel agents, for relapsed multiple myeloma.
AB - Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate approval of this medication by regulatory agencies has been an important step toward improving clinical outcomes in multiple myeloma. Although initially approved as a single agent for the treatment of multiply relapsed and/or refractory myeloma, in the USA, it is now widely used in the early relapse setting in combination with lenalidomide and dexamethasone. Carfilzomib has also been studied in combination with second-generation immunomodulatory drugs, histone deacetylase inhibitors, alkylating agents and other novel medications. In this review article, we will discuss the efficacy, safety, tolerability and quality of life of carfilzomib-based combination therapies, as well as novel agents, for relapsed multiple myeloma.
KW - Carfilzomib
KW - Multiple myeloma
KW - Novel drugs
KW - Relapsed and refractory myeloma
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85013304470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013304470&partnerID=8YFLogxK
U2 - 10.2147/OTT.S102756
DO - 10.2147/OTT.S102756
M3 - Review article
C2 - 28243125
AN - SCOPUS:85013304470
SN - 1178-6930
VL - 10
SP - 895
EP - 907
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -